Concepedia

Hiroshi Sootome

HS

9

Publications

1.3K

Citations

9

H-Index

2006

Active since

Affiliations

Taiho Pharmaceutical (Japan)(Current)

Tokushima University

Hiroshi Sootome is an author at Taiho Pharmaceutical (Japan) specializing in medicine, tumor biology, and cancer research.

Top concepts

Publications per year

2006–2024

9

Publications

9

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru et al. · Molecular Cancer Therapeutics · 2010 · 926 citations · Full text

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 184 citations · Full text

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa et al. · ACS Medicinal Chemistry Letters · 2023 · 31 citations · Full text

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh et al. · Molecular Cancer Therapeutics · 2013 · 28 citations

, , +16

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

Love Goyal, Daniel DiToro, Francesco Facchinetti et al. · Annals of Oncology · 2024 · 26 citations

, , +9

Rows per page

1–5 of 9